- Home
- HRZN vs CRVS Comparison
HRZN vs CRVS Comparison
Compare HRZN & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRZN
- CRVS
- Stock Information
- Founded
- HRZN 2008
- CRVS 2014
- Country
- HRZN United States
- CRVS United States
- Employees
- HRZN N/A
- CRVS N/A
- Industry
- HRZN Finance/Investors Services
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- HRZN Finance
- CRVS Health Care
- Exchange
- HRZN Nasdaq
- CRVS Nasdaq
- Market Cap
- HRZN 295.3M
- CRVS 305.4M
- IPO Year
- HRZN 2010
- CRVS 2016
- Fundamental
- Price
- HRZN $6.90
- CRVS $5.75
- Analyst Decision
- HRZN Hold
- CRVS Strong Buy
- Analyst Count
- HRZN 4
- CRVS 4
- Target Price
- HRZN $7.81
- CRVS $15.00
- AVG Volume (30 Days)
- HRZN 684.1K
- CRVS 518.7K
- Earning Date
- HRZN 08-07-2025
- CRVS 08-07-2025
- Dividend Yield
- HRZN 19.13%
- CRVS N/A
- EPS Growth
- HRZN N/A
- CRVS N/A
- EPS
- HRZN N/A
- CRVS N/A
- Revenue
- HRZN $97,144,000.00
- CRVS N/A
- Revenue This Year
- HRZN $0.51
- CRVS N/A
- Revenue Next Year
- HRZN $9.90
- CRVS N/A
- P/E Ratio
- HRZN N/A
- CRVS N/A
- Revenue Growth
- HRZN N/A
- CRVS N/A
- 52 Week Low
- HRZN $6.77
- CRVS $2.54
- 52 Week High
- HRZN $11.15
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- HRZN 30.61
- CRVS 65.10
- Support Level
- HRZN $6.86
- CRVS $5.28
- Resistance Level
- HRZN $6.96
- CRVS $5.64
- Average True Range (ATR)
- HRZN 0.09
- CRVS 0.30
- MACD
- HRZN -0.00
- CRVS 0.03
- Stochastic Oscillator
- HRZN 15.00
- CRVS 77.70
About HRZN Horizon Technology Finance Corporation
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).